Business Context and Reporting Period
Company: OraSure Technologies, Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2010
Business Overview: The company develops, manufactures, and markets oral fluid diagnostic products, specimen collection devices, and cryosurgical medical devices. Key products include the OraQuick HIV and HCV tests, Intercept drug testing systems, and Histofreezer cryosurgical systems. The company operates primarily in the United States and Europe.
Key Financial Metrics
| Metric | Q1 2010 | Q1 2009 |
|---|---|---|
| Total Revenues | $17,945,524 | $17,256,451 |
| Gross Profit | $11,404,062 | $10,972,072 |
| Gross Margin | 64% | 64% |
| Operating Loss | $(2,175,700) | $(1,860,242) |
| Net Loss | $(2,195,374) | $(1,617,961) |
| Loss Per Share (Basic & Diluted) | $(0.05) | $(0.04) |
| Cash and Cash Equivalents | $69,374,434 | $52,390,160 (End of Q1 2009) |
| Short-term Investments | $3,986,000 | $4,736,730 (Dec 31, 2009) |
| Total Debt (Current + Long-term) | $8,166,680 | $8,301,440 (Dec 31, 2009) |
| Working Capital | $86,583,352 | $89,434,543 (Dec 31, 2009) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 4% to $17.9 million, driven by a 310% increase in licensing and product development revenue (primarily a $1.0 million milestone payment from Merck for the OraQuick HCV test) and a 40% increase in cryosurgical systems sales. These gains were partially offset by a 9% decline in infectious disease testing revenues.
- Net Loss Expansion: Net loss increased to $2.2 million from $1.6 million year-over-year. This was due to higher operating expenses (Sales and Marketing up 13%; G&A up 7%) and lower interest income, despite a 7% reduction in R&D expenses.
- Cash Flow: Net cash used in operating activities increased to $5.0 million from $2.7 million in the prior year, largely due to the net loss and payments of accrued expenses (royalties and bonuses). Cash and cash equivalents decreased by $5.6 million during the quarter.
- Product Mix Shifts:
- Infectious Disease: OraQuick HIV sales declined 7% due to lower average selling prices and reduced public health funding.
- Cryosurgical: International OTC sales surged 184% due to a distributor launch in Brazil, offsetting declines in the European professional market.
Guidance, Outlook, and Risks
- Outlook: Management expects R&D costs to increase in 2010 due to clinical trials for HIV OTC and HCV products. Capital expenditures are expected to be approximately $2.0 million for the remainder of the year. The company believes its current cash position is sufficient to fund operations for at least the next twelve months.
- Recent Developments: The OraQuick HCV test received CE mark approval and was commercially launched in Europe in April 2010. The company entered into a settlement with an HIV peptide supplier, paying $2.1 million to terminate royalty obligations and secure a license.
- Risks and Contingencies:
- Economic Conditions: Ongoing economic downturns and reduced government funding may adversely affect customer purchasing power and sales cycles.
- Legal Proceedings: The company is engaged in patent infringement litigation in the UK regarding its cryosurgical technology against D.D.D. Limited and others.
- Supply Chain: Reliance on sole-source providers for critical components (e.g., HIV peptides) poses a risk if supply is disrupted.
- Competition: Intense competition in HIV testing and potential threats from "home-brew" assays in the substance abuse market.
Investor Verification Checklist
- Milestone Revenue Sustainability: Verify the timing and likelihood of future milestone payments from the Merck collaboration, as the $1.0 million payment significantly boosted Q1 licensing revenue.
- Public Health Funding Trends: Monitor state and local government funding levels, as reduced funding directly correlates with the decline in OraQuick HIV sales.
- International Distributor Performance: Assess the sustainability of the 184% growth in international OTC cryosurgical sales, which was driven by a specific distributor launch in Brazil.
- Patent Litigation Status: Track the outcome of the UK patent infringement lawsuit regarding the cryosurgical product, as a loss could impact future international sales.
- Debt Covenants: Confirm continued compliance with the Comerica Bank credit agreement covenants (quick ratio, liquidity, tangible net worth), especially given the company's accumulated deficit.